- Home
- GAM vs VERA Comparison
GAM vs VERA Comparison
Compare GAM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- VERA
- Stock Information
- Founded
- GAM 1927
- VERA 2016
- Country
- GAM United States
- VERA United States
- Employees
- GAM N/A
- VERA N/A
- Industry
- GAM Investment Managers
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- GAM Finance
- VERA Health Care
- Exchange
- GAM Nasdaq
- VERA Nasdaq
- Market Cap
- GAM 1.4B
- VERA 1.4B
- IPO Year
- GAM N/A
- VERA 2021
- Fundamental
- Price
- GAM $61.52
- VERA $24.76
- Analyst Decision
- GAM
- VERA Buy
- Analyst Count
- GAM 0
- VERA 8
- Target Price
- GAM N/A
- VERA $64.29
- AVG Volume (30 Days)
- GAM 20.1K
- VERA 1.8M
- Earning Date
- GAM 01-01-0001
- VERA 11-06-2025
- Dividend Yield
- GAM 5.74%
- VERA N/A
- EPS Growth
- GAM N/A
- VERA N/A
- EPS
- GAM 11.67
- VERA N/A
- Revenue
- GAM N/A
- VERA N/A
- Revenue This Year
- GAM N/A
- VERA N/A
- Revenue Next Year
- GAM N/A
- VERA N/A
- P/E Ratio
- GAM $3.95
- VERA N/A
- Revenue Growth
- GAM N/A
- VERA N/A
- 52 Week Low
- GAM $37.32
- VERA $18.53
- 52 Week High
- GAM $46.48
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- GAM 52.55
- VERA 60.41
- Support Level
- GAM N/A
- VERA $22.72
- Resistance Level
- GAM $61.79
- VERA $25.29
- Average True Range (ATR)
- GAM 0.60
- VERA 1.21
- MACD
- GAM -2.19
- VERA 0.17
- Stochastic Oscillator
- GAM 99.37
- VERA 87.04
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.